Regeneron presented new clinical data at ESMO 2026 on Libtayo use in high-risk CSCC and cancer-associated thrombosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results